@EASLedu brings you the latest on #liver research & education. Visit #EASLCampus ----------------- EASL does not express any political opinion. RT ≠ endorsement
Joined January 2016
- Tweets19.9K
- Following719
- Followers13.9K
- Likes10.6K
Pinned Tweet
#LiverX, how would you approach this case? 🤔
👉#HCC without cirrhosis.
👉Early recurrence.
👉Difficult treatment decisions.
There's still time to register for the #EASLMTB happening tonight and join the discussion!
More information below👇
@FRPonziani @BernharScheiner @TZ_Hirsch @LynnSavic @FrancqueSven @MattiasMandorf1
🩺 One complex case. Key clinical questions. Expert insights.
Explore the case of a 44-year-old woman with HCC arising without cirrhosis or underlying liver disease. From surgical resection and recurrence management to liver transplantation, discover the clinical challenges and treatment considerations discussed by our experts.
🔬 Join our upcoming Molecular Tumour Board, next Wednesday!
Register now: easl-eu.zoom.us/webinar/regi…
ALT EASL Molecular Tumour Board poster for "HCC in non-cirrhotic liver" event on Wednesday, 28 October 2026, from 18:00-19:00 CET. Features headshots of Francesca Romana Ponziani, Bernhard Scheiner, Theo Hirsch, Christian Toso, Michail Doukas, and Lynn Jeanette Savic. Includes "Register now!" prompt. Background has a pink, organic texture.
🎙️ Tune in for a thought-provoking discussion on one of the key challenges in #HCC care.
Plenty of questions, not always straightforward answers!🧐
More info below 👇
#TalkLiverToMe #LiverX
📊 How should HCC surveillance evolve as risk profiles change?
This new episode of #TalkLiverToMe explores the evidence behind patient selection, surveillance timing and modality choice, while addressing persistent variation between guidelines and the limitations of current surveillance strategies.
Now on EASL Campus: easlcampus.eu/tltm/episode-2…
Also on Spotify: open.spotify.com/episode/5TH…
and Apple Podcasts: podcasts.apple.com/ch/podcas…
ALT The image is an announcement for a talk titled "Hepatocellular Carcinoma: Who to screen, when, and how?" It's hosted by Mattias Mandorfer with Peter Jepsen and Amit Singal. The background features hexagons and the logos for "Talk to Me Liver" and EASL, The Home of Hepatology. The text "Available now!" is displayed in the top left corner.
EASL Education retweeted
HCC surveillance: A simple, pragmatic decision ... yeah, right! 🤡
Ingredients:
1💡Hepatoepidemiologist from 🇩🇰 , where cirrhosis per se is NOT an indication
1 🇺🇸 KOL
Honestly, this was the most exciting TLTM episode I moderated so far!
Don't miss it #LiverTwitter 🍿
In the next #TalkLiverToMe, experts revisit the fundamentals of hepatocellular carcinoma surveillance, with a practical look at patient selection, timing and the modalities available for early detection.
Tune in this Wednesday on your Spotify, Apple Podcasts or EASL Campus to listen to this interactive discussion.
More information: easl.eu/event/hepatocellular…
📢New #TalkLiverToMe out tomorrow!!
Who should undergo #HCC surveillance, when should it start, and which tools offer the best chance of early detection?
Don't forget to tune in! 😁
@MattiasMandorf1 @docamitgs @NaultJC @BCLC_group
#LiverX
In the next #TalkLiverToMe, experts revisit the fundamentals of hepatocellular carcinoma surveillance, with a practical look at patient selection, timing and the modalities available for early detection.
Tune in this Wednesday on your Spotify, Apple Podcasts or EASL Campus to listen to this interactive discussion.
More information: easl.eu/event/hepatocellular…
EASL Education retweeted
📢 Calling all EASL Young Investigators with valid membership! Help us improve the EASL CPG Tool by testing it and sharing your experience.
Your feedback will help us enhance its usability, functionality, and clinical relevance!
How can you contribute?
- Explore and test the EASL CPG Tool
- Share your experience and suggestions through our feedback survey
📅 Deadline: 8 November 2026
🔗 Access the tool: easl.eu/llm-prototype-testin…
Your insights matter! Take this opportunity to contribute to the development of a tool designed to make EASL Clinical Practice Guidelines more accessible and easier to use in daily practice.
Thank you for helping us improve EASL's digital resources!
#LiverTwitter #LiverX
EASL Education retweeted
How well do you know your Guidelines? Test yourself today as we examine the case of a 63-year-old man presented with painless jaundice, pruritus and a 3 kg weight loss over the previous 4 weeks, ECOG PS 1.
Take the quiz now: easlcampus.eu/quiz/question/…
ALT The image features the EASL Quiz logo on the left, with the text "Test your Guidelines Knowledge!" Below is a red button labeled "Liver Tumours." On the right, there's a medical illustration of a human torso highlighting the liver in red. The background is blue.
🔬 Can #HCC develop in the absence of cirrhosis or underlying liver disease? And how should we approach treatment when recurrence occurs?
Join the next #EASLMTB as a multidisciplinary panel of experts explores a challenging case of non-cirrhotic HCC, examining the evidence, debating treatment decisions and tackling the challenges of managing recurrence and selecting patients for liver transplantation.
More information below
👇👇👇
@FRPonziani @BernharScheiner @TZ_Hirsch @LynnSavic
#LiverX
🔬 HCC without underlying liver disease: What are the challenges?
Join our upcoming Molecular Tumour Board to explore the molecular characteristics of hepatocellular carcinoma, strategies for managing high-risk recurrence, and the potential role of liver transplantation in selected patients.
📅 Don’t miss this case-based expert discussion! Live on Wednesday, 28 October 2026.
Register now: easl-eu.zoom.us/webinar/regi…
ALT EASL Molecular Tumour Board poster for "HCC in non-cirrhotic liver" event on Wednesday, 28 October 2026, from 18:00-19:00 CET. Features headshots of Francesca Romana Ponziani, Bernhard Scheiner, Theo Hirsch, Christian Toso, Michail Doukas, and Lynn Jeanette Savic. Includes "Register now!" prompt. Background has a pink, organic texture.
EASL Education retweeted
#Baveno VIII consensus in portal hypertension #CSPH
Full Consensus Report now @JHepatology @EASLnews
journal-of-hepatology.eu/art…
🧠 This week's #TalkLiverToMe explores the complex interplay between liver health, the brain, addiction and mental health. Well worth a listen!
More info below👇👇
@IsraelsenMads @vtkronsten @FLASH_OUH @OUHhospital @MaudsleyNHS
#LiverX #TalkLiverToMe
New episode out! Tune in #TalkLivertoMe for a discussion on psychohepatology, the gut–liver–brain axis, addiction biology, trauma, PTSD, and integrated approaches to care.
Listen now on EASL Campus: easlcampus.eu/tltm/episode-1…
Also on Spotify and Apple Podcasts!
Host an EASL School in 2028: easl.eu/what-we-do/education…
EASL Education retweeted
New episode out! Tune in #TalkLivertoMe for a discussion on psychohepatology, the gut–liver–brain axis, addiction biology, trauma, PTSD, and integrated approaches to care.
Listen now on EASL Campus: easlcampus.eu/tltm/episode-1…
Also on Spotify and Apple Podcasts!
Host an EASL School in 2028: easl.eu/what-we-do/education…
Don't miss #TalkLiverToMe this Wednesday!!
@IsraelsenMads @vtkronsten @FLASH_OUH @OUHhospital @MaudsleyNHS
#LiverX
Are we overlooking mental health in liver disease care?
In this episode of #TalkLivertoMe we explore psychohepatology, from the gut–liver–brain axis to the links between liver disease, addiction, trauma, depression, and anxiety.
easl.eu/event/psychohepatolo…
Host an EASL School in 2028: easl.eu/what-we-do/education…
#MASLDAcademy Module 2:
Thank you to the organisers and congratulations to all the participants for completing this module👏👏
@FrancqueSven @kvvanten @UZAnieuws
@UAntwerpen
#LiverTwitter
Module 2 of the EASL MASLD Guidelines Academy took place on 8-9 October in Antwerp, Belgium, taking participants on a deeper dive into MASLD.
Expert-led sessions explored MASLD pathophysiology and its links with cardiovascular disease. Clinical cases and interactive workshops also examined the role of liver biopsy and non-invasive tests in clinical practice.
#LiverTwitter #LiverX
🇧🇪 Module 2 of the EASL MASLD Guidelines Academy is underway at UZA – Antwerp University Hospital!
Participants are taking a deeper dive into MASLD pathophysiology, cardiovascular disease, liver biopsy, and non-invasive assessment through expert-led sessions, clinical cases, and interactive workshops.
@UZAnieuws @FrancqueSven @kvvanten
#LiverX #MASLD #MASLDAcademy
EASL Education retweeted
The EASL Experimental & Translational Science School: The Spatial Biology of Liver Disease just ended after two great days of learning and networking in Utrecht, the Netherlands! 🔥
Participants came together for hands-on training, expert insights, and collaborative problem-solving around cutting-edge spatial omics technologies in liver research.
From Hyperion, CosMx/GeoMx and MALDI imaging to the Spatial Liver Biology Hackathon, this EASL School offered an inspiring two days of learning, exchange, and innovation.
#LiverTwitter #LiverX
📢#EASLMolecularTumourBoard happening today!
Have you registered yet? 👀
👇👇👇
You can still register for today's DeepDive webinar on the latest updates in the EASL CPGs on the management of hepatocellular carcinoma! The discussion will include diagnostic strategies, selection of candidates for surgery and locoregional therapies, and treatment adaptation according to response to systemic therapy.
📅TODAY, 7 October, 18:00 CEST
🔗 easl-eu.zoom.us/webinar/regi…
🎙️Discover the New #TalkLiverToMe episode on Resmetirom and Semaglutide as MASH-targeted therapies!
@JHepatology @DebbieShawcros1 @Tacke_lab @gastaldelli_amy @EASOobesity @EASDnews
#LiverX
In this new episode of #TalkLiverToMe, experts discuss the practical use of resmetirom and semaglutide, based on the 2026 EASL–EASD–EASO Guidance.
Who should be treated, when should therapy start, and how should response be monitored?
Listen on EASL Campus: easlcampus.eu/tltm/episode-1…
Also on Spotify: open.spotify.com/episode/4Wt…
and Apple Podcasts: podcasts.apple.com/ch/podcas…
EASL Education retweeted
What if the future of hepatology is not just about treating liver disease, but preventing it before it starts?
Liver health is shaped by far more than what happens in the clinic. Alcohol, nutrition, metabolic health, socioeconomic inequalities, stigma, commercial influences and public policy all play a role in who develops liver disease, and who gets diagnosed in time.
That's why preventive hepatology matters. But the question many clinicians ask us is: what can I actually do about that from my clinic?
🎯 The new EASL Preventive Hepatology Course sets out to answer exactly that. Built on the roadmap of the EASL–Lancet Commission 2.0, it gives hepatologists and allied health professionals:
→ The latest evidence on social and commercial determinants as drivers of liver disease
→ A clear view of which policies genuinely work, and which don't
→ Practical tools to bring prevention and early detection into everyday practice
→ A way into advocacy, for those who want to go further and get involved
Clinicians are among the most trusted voices in health policy. This free course is about helping that voice carry further.
👉 Module 1 is open now: easlcampus.eu/course/prevent…
Prevention starts with knowledge. Let's put it at the heart of liver health.
#Hepatology #PreventiveHepatology #LiverHealth #PublicHealth #EASL
🚨Deadline extended 🚨
The deadline for the #EASLSchools 2027 has been extended to 5 October!
Fine-tune your application and take your pick from 4 exciting Schools across Europe.
🔗easl.eu/what-we-do/education…
@FrancqueSven @MattiasMandorf1 @IvaKosuta @manna_555 @ChokshiLab @docberza @VirginiaHdezGea @ReibergerThomas
#LiverX
The deadline for the EASL Schools 2027 has been extended! Time to fine tune your applications and submit them on 5 October!
🔗 easl.eu/what-we-do/education…
EASL Education retweeted
🆕 EASL-EASD-EASO guidance on resmetirom and semaglutide as #MASH-targeted therapy
💉#Semaglutide: preferred in patients with obesity, T2D or high cardiovascular risk
💊#Resmetirom: prioritised in those without obesity or unable to use GLP-1RAs
🔗bit.ly/4ynVQpR
